


Obr. 2. Molekulární heterogenita NSCLC a molekulárně cílené léky



Obr. 3. Přehled indikací cílené léčby NSCLC podle NCCN guidelines

NCCN National Comprehensive Cancer Network® NCCN Guidelines Version 3.2022 Non-Small Cell Lung Cancer NCCN Guidelines Index Table of Contents Discussion		
TARGETED THERAPY OR IMMUNOTHERAPY FOR ADVANCED OR METASTATIC DISEASE ^{a,b}		
EGFR Exon 19 Deletion or L858R • First-line therapy > Afatinib ¹ > Erlotinib ² > Dacomitinib ³ > Gefitinib ^{4,5} > Osimertinib ⁶ > Erlotinib + ramucirumab ⁷ > Erlotinib + bevacizumab ^c (nonsquamous) ⁸ • Subsequent therapy > Osimertinib ⁹	ALK Rearrangement Positive • First-line therapy > Alectinib ^{15,16} > Brigatinib ¹⁷ > Ceritinib ¹⁸ > Crizotinib ^{15,19} > Lorlatinib ²⁰ • Subsequent therapy > Alectinib ^{21,22} > Brigatinib ²³ > Ceritinib ²⁴ > Lorlatinib ²⁵	MET Exon 14 Skipping Mutation • First-line therapy/Subsequent therapy > Capmatinib ³⁵ > Crizotinib ³⁶ > Tepotinib ³⁷
EGFR S768I, L861Q, and/or G719X First-line therapy > Afatinib ^{1,10} > Erlotinib ² > Dacomitinib ³ > Gefitinib ^{4,5} > Osimertinib ^{6,11} • Subsequent therapy > Osimertinib ⁹	ROS1 Rearrangement Positive • First-line therapy > Ceritinib ²⁴ > Crizotinib ²⁷ > Entrectinib ²⁸ • Subsequent therapy > Lorlatinib ²⁹ > Entrectinib ²⁸	RET Rearrangement Positive • First-line therapy/Subsequent therapy > Selpercatinib ³⁸ > Pralsetinib ³⁹ > Cabozantinib ^{40,41}
EGFR Exon 20 Insertion Mutation Positive • Subsequent therapy > Amivantamab-vmjw ¹² > Mobocertinib ¹³	BRAF V600E Mutation Positive • First-line therapy > Dabrafenib/trametinib ^{30,31} > Dabrafenib ³⁰ > Vemurafenib • Subsequent therapy > Dabrafenib/trametinib ^{31,32}	PD-L1 ≥1% • First-line therapy ^d > Pembrolizumab ⁴²⁻⁴⁴ > (Carboplatin or cisplatin)/pemetrexed/ pembrolizumab (nonsquamous) ^{45,46} > Carboplatin/paclitaxel/bevacizumab ^c / atezolizumab (nonsquamous) ⁴⁷ > Carboplatin/(paclitaxel or albumin-bound paclitaxel)/pembrolizumab (squamous) ⁴⁸ > Carboplatin/albumin-bound paclitaxel/ atezolizumab (nonsquamous) ⁴⁸ > Nivolumab/ipilimumab ⁴⁹ > Nivolumab/ipilimumab/pemetrexed/ (carboplatin or cisplatin) (nonsquamous) ⁵⁰ > Nivolumab/ipilimumab/paclitaxel/carboplatin (squamous) ⁵⁰
KRAS G12C Mutation Positive • Subsequent therapy > Sotorasib ¹⁴	NTRK1/2/3 Gene Fusion Positive • First-line/Subsequent therapy > Larotrectinib ³³ > Entrectinib ³⁴	PD-L1 ≥50% (in addition to above) • First-line therapy ^d > Atezolizumab ⁵¹ > Cemiplimab-rwlc ⁵²